Axogen, Inc. (LON:0HKD)
16.31
-0.37 (-2.22%)
At close: Sep 15, 2025
Axogen Revenue
Axogen had revenue of $56.66M USD in the quarter ending June 30, 2025, with 18.26% growth. This brings the company's revenue in the last twelve months to $203.27M, up 17.17% year-over-year. In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth.
Revenue (ttm)
$203.27M
Revenue Growth
+17.17%
P/S Ratio
3.82
Revenue / Employee
$449.71K
Employees
452
Market Cap
566.49M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Axogen News
- 11 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN - Benzinga
- 23 days ago - Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted - Investor's Business Daily
- 24 days ago - Axogen falls 16% after FDA delays Avance Nerve Graft decision to December - Seeking Alpha
- 24 days ago - Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft - GlobeNewsWire
- 5 weeks ago - Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
- 6 weeks ago - Axogen (AXGN) Q2 Revenue Jumps 18% - The Motley Fool
- 6 weeks ago - Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Axogen, Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha